Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: PIK3CB

Gene summary for PIK3CB

Gene summary.

Gene information	Species	Human
	Gene symbol	PIK3CB
	Gene ID	5291
	Gene name	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta
	Gene Alias	P110BETA
	Cytomap	3q22.3
	Gene Type	protein-coding
	GO ID	GO:0000165
	UniProtAcc	B4DER4

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
5291	PIK3CB	CCI_1	Human	Cervix	CC	1.05e-03	8.02e-01	0.528
5291	PIK3CB	CCI_2	Human	Cervix	CC	2.19e-04	6.88e-01	0.5249
5291	PIK3CB	CCI_3	Human	Cervix	CC	2.88e-07	6.84e-01	0.516
5291	PIK3CB	HTA11_3410_2000001011	Human	Colorectum	AD	3.49e-13	-5.46e-01	0.0155
5291	PIK3CB	HTA11_347_2000001011	Human	Colorectum	AD	6.10e-04	4.24e-01	-0.1954
5291	PIK3CB	HTA11_866_3004761011	Human	Colorectum	AD	1.07e-05	-4.48e-01	0.096
5291	PIK3CB	HTA11_10711_2000001011	Human	Colorectum	AD	2.25e-02	-2.67e-01	0.0338
5291	PIK3CB	HTA11_7696_3000711011	Human	Colorectum	AD	2.08e-10	-3.80e-01	0.0674
5291	PIK3CB	HTA11_99999970781_79442	Human	Colorectum	MSS	5.70e-14	-4.34e-01	0.294
5291	PIK3CB	HTA11_99999974143_84620	Human	Colorectum	MSS	1.14e-11	-4.94e-01	0.3005
5291	PIK3CB	F007	Human	Colorectum	FAP	3.57e-04	-4.16e-01	0.1176
5291	PIK3CB	A001-C-207	Human	Colorectum	FAP	3.39e-03	-1.93e-01	0.1278
5291	PIK3CB	A015-C-203	Human	Colorectum	FAP	1.45e-29	-4.98e-01	-0.1294
5291	PIK3CB	A015-C-204	Human	Colorectum	FAP	3.70e-08	-4.00e-01	-0.0228
5291	PIK3CB	A014-C-040	Human	Colorectum	FAP	4.58e-03	-3.61e-01	-0.1184
5291	PIK3CB	A002-C-201	Human	Colorectum	FAP	1.95e-16	-3.87e-01	0.0324
5291	PIK3CB	A002-C-203	Human	Colorectum	FAP	7.10e-04	-1.69e-01	0.2786
5291	PIK3CB	A001-C-119	Human	Colorectum	FAP	2.46e-08	-4.76e-01	-0.1557
5291	PIK3CB	A001-C-108	Human	Colorectum	FAP	7.35e-17	-2.93e-01	-0.0272
5291	PIK3CB	A002-C-205	Human	Colorectum	FAP	2.89e-23	-4.38e-01	-0.1236

Page: 1 2 3 4 5 6 7

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:004206010	Cervix	CC	wound healing	109/2311	422/18723	1.84e-14	1.57e-11	109
GO:001081010	Cervix	CC	regulation of cell-substrate adhesion	69/2311	221/18723	8.57e-14	5.69e-11	69
GO:00315898	Cervix	CC	cell-substrate adhesion	96/2311	363/18723	1.48e-13	8.85e-11	96
GO:009013210	Cervix	CC	epithelium migration	90/2311	360/18723	2.45e-11	6.11e-09	90
GO:00016679	Cervix	CC	ameboidal-type cell migration	110/2311	475/18723	2.66e-11	6.36e-09	110
GO:001063110	Cervix	CC	epithelial cell migration	89/2311	357/18723	3.72e-11	8.54e-09	89
GO:009013010	Cervix	CC	tissue migration	90/2311	365/18723	5.42e-11	1.05e-08	90
GO:000989610	Cervix	CC	positive regulation of catabolic process	109/2311	492/18723	5.26e-10	6.99e-08	109
GO:00510566	Cervix	CC	regulation of small GTPase mediated signal transduction	75/2311	302/18723	1.54e-09	1.74e-07	75
GO:001063210	Cervix	CC	regulation of epithelial cell migration	72/2311	292/18723	4.52e-09	4.43e-07	72
GO:00072656	Cervix	CC	Ras protein signal transduction	79/2311	337/18723	9.49e-09	7.77e-07	79
GO:00019528	Cervix	CC	regulation of cell-matrix adhesion	40/2311	128/18723	1.32e-08	1.04e-06	40
GO:00071608	Cervix	CC	cell-matrix adhesion	60/2311	233/18723	1.58e-08	1.23e-06	60
GO:003133110	Cervix	CC	positive regulation of cellular catabolic process	91/2311	427/18723	9.64e-08	5.25e-06	91
GO:00106349	Cervix	CC	positive regulation of epithelial cell migration	47/2311	176/18723	1.73e-07	8.01e-06	47
GO:000226210	Cervix	CC	myeloid cell homeostasis	43/2311	157/18723	2.66e-07	1.12e-05	43
GO:004887210	Cervix	CC	homeostasis of number of cells	61/2311	272/18723	2.17e-06	6.55e-05	61
GO:00719007	Cervix	CC	regulation of protein serine/threonine kinase activity	75/2311	359/18723	2.76e-06	8.02e-05	75
GO:005134810	Cervix	CC	negative regulation of transferase activity	60/2311	268/18723	2.77e-06	8.02e-05	60
GO:004593610	Cervix	CC	negative regulation of phosphate metabolic process	88/2311	441/18723	2.92e-06	8.27e-05	88

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0517120	Cervix	CC	Coronavirus disease - COVID-19	111/1267	232/8465	1.82e-33	5.90e-31	3.49e-31	111
hsa0520820	Cervix	CC	Chemical carcinogenesis - reactive oxygen species	92/1267	223/8465	4.71e-22	5.09e-20	3.01e-20	92
hsa0502018	Cervix	CC	Prion disease	98/1267	273/8465	2.64e-18	1.42e-16	8.42e-17	98
hsa0541520	Cervix	CC	Diabetic cardiomyopathy	76/1267	203/8465	1.40e-15	6.46e-14	3.82e-14	76
hsa0501018	Cervix	CC	Alzheimer disease	113/1267	384/8465	9.67e-14	3.92e-12	2.32e-12	113
hsa0493218	Cervix	CC	Non-alcoholic fatty liver disease	58/1267	155/8465	3.58e-12	1.05e-10	6.23e-11	58
hsa0541820	Cervix	CC	Fluid shear stress and atherosclerosis	50/1267	139/8465	5.71e-10	1.32e-08	7.81e-09	50
hsa0513220	Cervix	CC	Salmonella infection	74/1267	249/8465	1.33e-09	2.54e-08	1.50e-08	74
hsa0541720	Cervix	CC	Lipid and atherosclerosis	65/1267	215/8465	6.47e-09	1.10e-07	6.52e-08	65
hsa0516720	Cervix	CC	Kaposi sarcoma-associated herpesvirus infection	60/1267	194/8465	9.74e-09	1.58e-07	9.33e-08	60
hsa0516318	Cervix	CC	Human cytomegalovirus infection	65/1267	225/8465	4.59e-08	6.47e-07	3.83e-07	65
hsa0513120	Cervix	CC	Shigellosis	69/1267	247/8465	7.64e-08	1.03e-06	6.10e-07	69
hsa0520516	Cervix	CC	Proteoglycans in cancer	60/1267	205/8465	9.13e-08	1.18e-06	7.00e-07	60
hsa0421810	Cervix	CC	Cellular senescence	49/1267	156/8465	1.30e-07	1.63e-06	9.61e-07	49
hsa0451010	Cervix	CC	Focal adhesion	59/1267	203/8465	1.53e-07	1.84e-06	1.09e-06	59
hsa0481016	Cervix	CC	Regulation of actin cytoskeleton	64/1267	229/8465	2.24e-07	2.59e-06	1.53e-06	64
hsa0491520	Cervix	CC	Estrogen signaling pathway	44/1267	138/8465	3.55e-07	3.97e-06	2.35e-06	44
hsa0516920	Cervix	CC	Epstein-Barr virus infection	57/1267	202/8465	7.30e-07	7.39e-06	4.37e-06	57
hsa0516620	Cervix	CC	Human T-cell leukemia virus 1 infection	61/1267	222/8465	8.13e-07	7.98e-06	4.72e-06	61
hsa0467020	Cervix	CC	Leukocyte transendothelial migration	36/1267	114/8465	5.22e-06	4.83e-05	2.86e-05	36

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

PIK3CB

SNV

Missense_Mutation

c.1491N>C

p.Glu497Asp

p.E497D

P42338

protein_coding

tolerated(0.18)

benign(0.02)

TCGA-A2-A0SY-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Hormone Therapy

arimidex

PIK3CB

SNV

Missense_Mutation

novel

c.1933N>T

p.Val645Leu

p.V645L

P42338

protein_coding

deleterious(0.01)

probably_damaging(0.932)

TCGA-A8-A0A2-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

tamoxiphen

PIK3CB

SNV

Missense_Mutation

rs774181749

c.308N>A

p.Arg103Lys

p.R103K

P42338

protein_coding

tolerated(0.35)

benign(0.206)

TCGA-A8-A0A7-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

PIK3CB

SNV

Missense_Mutation

c.2302N>T

p.Leu768Phe

p.L768F

P42338

protein_coding

deleterious(0.05)

benign(0.41)

TCGA-AN-A04A-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

PIK3CB

SNV

Missense_Mutation

c.911T>G

p.Ile304Arg

p.I304R

P42338

protein_coding

tolerated(0.74)

benign(0.065)

TCGA-AN-A0AM-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

PIK3CB

SNV

Missense_Mutation

c.3040G>A

p.Glu1014Lys

p.E1014K

P42338

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-AO-A0JC-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

fluorouracil

PIK3CB

SNV

Missense_Mutation

rs768628634

c.2189N>T

p.Ala730Val

p.A730V

P42338

protein_coding

tolerated(0.11)

benign(0.101)

TCGA-D8-A1J8-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

nolvadex

PIK3CB

SNV

Missense_Mutation

c.3151N>A

p.Glu1051Lys

p.E1051K

P42338

protein_coding

deleterious(0.03)

possibly_damaging(0.459)

TCGA-D8-A1JC-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

adriamycin

PIK3CB

SNV

Missense_Mutation

c.1658A>G

p.Asn553Ser

p.N553S

P42338

protein_coding

tolerated(0.26)

benign(0.365)

TCGA-E2-A14Z-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

arimidex

PIK3CB

insertion

Nonsense_Mutation

novel

c.3128_3129insTTTTGTTGTCCTTCTTAATGTTCTCAGTCAAATAAATGAGTG

p.Gln1043delinsHisPheValValLeuLeuAsnValLeuSerGlnIleAsnGluTer

p.Q1043delinsHFVVLLNVLSQINE*

P42338

protein_coding

TCGA-AO-A0J9-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cyclophosphamide

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
5291	PIK3CB	CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, G PROTEIN COUPLED RECEPTOR	inhibitor	249565691	CHEMBL1086377
5291	PIK3CB	CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, G PROTEIN COUPLED RECEPTOR	inhibitor	BYL719	ALPELISIB
5291	PIK3CB	CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, G PROTEIN COUPLED RECEPTOR	inhibitor	BYL719	ALPELISIB
5291	PIK3CB	CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, G PROTEIN COUPLED RECEPTOR	inhibitor	CHEMBL2219421	RECILISIB
5291	PIK3CB	CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, G PROTEIN COUPLED RECEPTOR	inhibitor	249565646	PILARALISIB
5291	PIK3CB	CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, G PROTEIN COUPLED RECEPTOR	inhibitor	249565693
5291	PIK3CB	CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, G PROTEIN COUPLED RECEPTOR	inhibitor	CHEMBL2387080	TASELISIB
5291	PIK3CB	CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, G PROTEIN COUPLED RECEPTOR		SURAMIN	SURAMIN	15833899,11473364
5291	PIK3CB	CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, G PROTEIN COUPLED RECEPTOR	inhibitor	178102645
5291	PIK3CB	CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, G PROTEIN COUPLED RECEPTOR		Buparlisib	BUPARLISIB

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16